Your session is about to expire
← Back to Search
Prostaglandin Analog
OTX-TIC-Cohort 1 for Ocular Hypertension
Phase 1
Waitlist Available
Research Sponsored by Ocular Therapeutix, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma
Have IOP that is currently controlled as assessed by the Investigator Have open, normal appearing anterior chamber angles as determined by gonioscopy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up diurnal iop [6 months visit]
Awards & highlights
Study Summary
This trial is testing a new, sustained release eye drop to treat primary open-angle glaucoma or ocular hypertension.
Eligible Conditions
- Ocular Hypertension
- Open-Angle Glaucoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ diurnal iop [6 months visit]
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~diurnal iop [6 months visit]
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy outcome
Incidence of treatment emergent adverse events for each subject
Trial Design
4Treatment groups
Experimental Treatment
Group I: OTX-TIC-Cohort 4Experimental Treatment1 Intervention
5 µg (formulation 3) implant
Group II: OTX-TIC-Cohort 3Experimental Treatment1 Intervention
15 µg (formulation 2) implant
Group III: OTX-TIC-Cohort 2Experimental Treatment1 Intervention
26 µg (formulation1) implant
Group IV: OTX-TIC-Cohort 1Experimental Treatment1 Intervention
15 µg (formulation1) implant
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OTX-TIC
2018
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
Ocular Therapeutix, Inc.Lead Sponsor
53 Previous Clinical Trials
5,558 Total Patients Enrolled
4 Trials studying Ocular Hypertension
782 Patients Enrolled for Ocular Hypertension
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger